How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,417 results for

Topical Medication Quantity

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs

synthetic opioids as reported in the media and in other sources of information in Canada and the United States. Finally, the bulletin includes a discussion of the implications of this phenomenon for those working in: ? Public health and harm reduction ? Emergency medical services and emergency response services ? Laboratories ? Poison control centres ? Law enforcement Reports of Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs The following table provides a non (...) Bulletin: Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs Canadian Centre on Substance Abuse • Centre canadien de lutte contre les toxicomanies Page 12 Pag e 12 1 U.S. Food and Drug Administration. (2016). Counterfeit Medicine. Retrieved June 2, 2016, from www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/CounterfeitMedicine/ 2 Canadian Community Epidemiology Network on Drug Use. (2014). CCENDU Drug Alert: Increasing Availability of Counterfeit

2016 Canadian Centre on Substance Abuse

2. Herbal cannabis and pharmaceutical cannabinoid treatment following motor vehicle accidents: A state of the science review

of prescription drug therapy 1 1.2 ICBC prescription medication funding policy 2 1.3 Herbal cannabis and pharmaceutical cannabinoids in clinical medical practice in Canada 2 2.0 An overview of a graduated evidence-informed, ICBC funding model 3 2.1 Funding policy decisions within a graduated, evidence informed ICBC funding model 5 2.2 Pharmaceutical cannabinoid medications for regulatory approved indications (LEVEL 1) 6 2.3 Pharmaceutical cannabinoids for indications without regulatory approval (LEVEL 2) 6 (...) and a doctor’s prescription which, to some extent, it adjudicates as to the appropriateness of diagnosis and the type and volume of drugs prescribed. Decisions regarding funding of herbal cannabis and pharmaceutical cannabinoidss fit within this well established ICBC funding policy framework. 1.3 Herbal cannabis and pharmaceutical cannabinoids in clinical medical practice in Canada The application of scientific medical knowledge of herbal cannabis and pharmaceutical cannabinoid therapy to clinical medical

2020 Therapeutics Letter

3. Non-Drug Therapy and Prevention of Diabetes Mellitus by Dalk (Massage) Full Text available with Trip Pro

Non-Drug Therapy and Prevention of Diabetes Mellitus by Dalk (Massage) According to WHO estimation, the number of diabetic patients would reach about 591.9 million people in 2035. The tendency towards other kinds of treatment is increasing because of the high therapeutic expenditures and current medical complications. Positive results of massage in recent articles and the prominent role of dalk in Iranian traditional medicine led us to the present study review.Studying Iranian traditional (...) results were confirmed. For example, in DM, its effects in decreasing FBS and HBA1C are shown.According to Iranian traditional medicine and latest articles, dalk as a non-drug therapy and prevention manner is recommended.

2016 Iranian journal of medical sciences

4. Topical Medication Quantity

Topical Medication Quantity Topical Medication Quantity Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Topical Medication Quantity (...) Topical Medication Quantity Aka: Topical Medication Quantity , Fingertip Estimate of Topical Medication Quantity , Finger Tip unit , FTU , Rule of Hand From Related Chapters II. Definitions Rule of Hand One adult hand print (palmar surface of hand and fingers) is 0.8% (~1%) of body surface area One adult hand print requires 0.25 grams of topical medication per application Two adult hand prints require 0.5 grams of topical medication per application (1 Finger Tip unit) Four adult hand prints require 1

2018 FP Notebook

5. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response

, for example homecare medicines delivery services, may become disrupted during the pandemic and have plans in place to manage this. 2.2 Prescribe usual quantities of medicines to meet the patient's clinical needs. Prescribing larger quantities of medicines puts the supply chain at risk. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions (...) ://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 13Contents Contents Overview 4 1 Communicating with patients and minimising risk 5 2 Supplying medicines 7 3 Patients not known to have COVID-19 8 Treatment considerations 8 4 Patients known or suspected to have COVID-19 10 T opical treatment 10 Systemic treatment 10 5 Modifications to usual care 12 6 Healthcare workers 13 COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169) © NICE 2020

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

6. Scientific elaboration of concepts for the generation of data related to clinical practice and their evaluation for the purpose of benefit assessments of drugs §35a Social Code Book V - Rapid report

) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Concepts for the generation of routine practice data and their analysis for the benefit assessment of drugs according to §35a Social Code Book V (SGB V) Commissioning agency: Federal Joint Committee Commission awarded on: 2 May 2019 Internal Commission No.: A19-43 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685 (...) of the data collected within the framework of the respective generation of data. Methods Information retrieval and assessment According to the project outline, the development of the concept for the generation of routine practice data and their analysis for the benefit assessment of drugs according to §35a SGB V was supported by 3 modules: ? Empirical information from the benefit assessments of drugs according to the Act on the Reform of the Market for Medicinal Products (AMNOG, §35a SGB V). ? Exploratory

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

7. Preventing and Managing Infectious Diseases Among People who Inject Drugs in Ontario

withdrawal and often leaving against Preventing and Managing Infectious Diseases Among People who Inject Drugs in Ontario 16 Evidence >> Insight >> Action Type of challenge Challenge Description medical advice, resulting in them not being able to finish needed treatments for infectious disease. • Several panellists expressed frustration with the change in prescription guidelines that occurred in 2013, noting that they forced health professionals to restrict the quantity of opioids being prescribed (...) who inject drugs o This element could include efforts to prevent or help people to stop injecting drugs, efforts to reduce the risk of infection (e.g., needle-exchange programs, safe consumption/injection sites, and opioid analgesic therapy) and enhancing education efforts for people who inject drugs (e.g., to minimize risk of infectious diseases, identify early symptoms of infectious diseases, and know where to seek treatment when needed). o Generally, the evidence for this element supported

2019 McMaster Health Forum

8. A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable

A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically (...) to cyclosporine. Condition or disease Intervention/treatment Phase Atopic Dermatitis Drug: Baricitinib Drug: Placebo Drug: Topical corticosteroid Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 500 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled

2018 Clinical Trials

9. The Medication Pass Nutritional Supplement Program in Patients Receiving Medication

The Medication Pass Nutritional Supplement Program in Patients Receiving Medication Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses (...) Medication Pass Nutritional Supplement program (Med-Pass) Comparator ? Standard of care (i.e., not using Med-Pass, administering medication with water, juice, or ginger ale) ? No comparator Outcomes ? Clinical effectiveness and safety (e.g., patient harms and benefits, potential food/drug interactions) ? Evidence-based guidelines Study Designs Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies and evidence- based guidelines. Exclusion

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis Full Text available with Trip Pro

Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis Park KT, Perez F, Tsai R, Honkanen A, Bass D, Garber A Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of adding the probiotic VSL#3 to standard medical therapy for children with moderate-to-severe ulcerative colitis. The authors concluded that the addition of VSL#3 was not cost-effective, but small changes in the quality of life after surgery

2011 NHS Economic Evaluation Database.

11. Topical herbal therapies for treating osteoarthritis. Full Text available with Trip Pro

reported.Although the mechanism of action of the topical medicinal plant products provides a rationale basis for their use in the treatment of osteoarthritis, the quality and quantity of current research studies of effectiveness are insufficient. Arnica gel probably improves symptoms as effectively as a gel containing non-steroidal anti-inflammatory drug, but with no better (and possibly worse) adverse event profile. Comfrey extract gel probably improves pain, and Capsicum extract gel probably will not improve (...) Topical herbal therapies for treating osteoarthritis. Before extraction and synthetic chemistry were invented, musculoskeletal complaints were treated with preparations from medicinal plants. They were either administered orally or topically. In contrast to the oral medicinal plant products, topicals act in part as counterirritants or are toxic when given orally.To update the previous Cochrane review of herbal therapy for osteoarthritis from 2000 by evaluating the evidence on effectiveness

2013 Cochrane

12. Controlled drugs in peri-operative care

/competency/safe use of controlled drugs by theatre staff. • Medication Safety Officer/Medical Device Safety Officer o The CQC checks whether there is a medication safety officer appointed to link with the theatre team and the CDAO/pharmacy team around safe use of medicines and devices. • Implementation of relevant legislation and guidance o Whether the organisation’s controlled drugs policy takes account of relevant legislation, alerts and national guidance.7 Association of Anaesthetists | Controlled (...) -butyrolactone, which is not scheduled due to wide use in industry) are listed in one of five schedules to the regulations, based on an assessment of their medical therapeutic usefulness together with their potential harm when misused. Schedule 1 covers drugs that have no therapeutic value and are mainly used for research under a Home Office licence. Schedule 2 controlled drugs are subject to the greatest restrictions and Schedule 5 the least. Human medicines only contain controlled drugs in Schedules 2, 3

2019 Association of Anaesthetists of GB and Ireland

13. Review of the New Strategic Direction for Alcohol and Drugs – Phase 2

of Public Health in Ireland Table e6: Factors that hindered effectiveness Factors that hindered effectiveness Perceived result ‘Ever rising tide’ of drug and alcohol- related harm Services becoming overwhelmed, diversion of resources away from prevention at strategic and operational levels Rising complexity of service need Existing linear models of care become quickly obsolete, increasingly focussed on crisis care and quantity of service rather than quality of care and recovery model Lack of political (...) Review of the New Strategic Direction for Alcohol and Drugs – Phase 2 The Institute of Public Health in Ireland 1 Review of the New Strategic Direction for Alcohol and Drugs – Phase 2 A report prepared for the Department of Health in Northern Ireland by the Institute of Public Health in Ireland 1 Institute of Public Health in Ireland Review of the New Strategic Direction for Alcohol and Drugs – Phase 2 2018 A report prepared for the Department of Health in Northern Ireland by the Institute

2019 Institute of Public Health in Ireland

14. Closed-system transfer-devices for limiting exposure to cytotoxic anti-cancer drugs in healthcare professionals, patients and visitors

, the clinical importance of this reduction is unknown. ? Four studies reporting a range of guidelines for the safe-handling of hazardous drugs recommended implementation of training, personal protective equipment (PPE), CSTDs, medical surveillance and other safety measures, largely based on expert consensus. SHTG Evidence Synthesis | 3 Contents Definitions 4 Literature search 4 Introduction 4 Description of health problem 6 Health technology description 6 Clinical effectiveness 7 Cost effectiveness 14 (...) into, or extracted from, the vial 14 . The injector is used to attach a syringe to the drug vial access device or into an IV line device on IV tubing 14 . This forms dry, leak-proof connections during drug preparation and administration. The drugs are then agitated to mix, or inverted if unstable on agitation. 14 Then the drugs are extracted and a protective cap is placed on the syringe to prevent leaks. 14 Examples of commercial CSTDs available on the market include: ? OnGuard® (B Braun Medical Ltd

2019 SHTG Advice Statements

15. Use of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

, as well as structural abnormalities, making it possible to deliver novel drugs free from cardiac liabilities and guide personalized therapy. This article briefly reviews the challenges of cardio-oncology, the strengths and limitations of using human induced pluripotent stem cell–derived cardiomyocytes to represent clinical findings in the nonclinical research space, and future directions for their further use. In the United States and Europe, cancer is the second leading cause of death and morbidity (...) the safety and efficacy of currently available and future therapies. The focus of this scientific statement is the utility and potential promise of human induced pluripotent stem cell (hiPSC)–derived cardiomyocytes (hiPSC-CMs) in preclinical testing of drug-induced cardiotoxicity. Although there is overlap, it is useful to consider cardiotoxicity in 3 categories: electrophysiological abnormalities, contractile dysfunction, and structural toxicity. Although touching on all 3 categories, this review

2019 American Heart Association

16. Appropriate prescribing of psychotropic medication for non-cognitive symptoms in people with dementia

Grading of Recommendations Assessment, Development and Evaluation GDG Guideline Development Group GDP Global Domestic Product MCI Mild Cognitive Impairment MHBC Ministry of Health British Columbia MHRA Medicines and Healthcare products Regulatory Agency NCEC National Clinical Effectiveness Committee NHMRC National Health and Medical Research Council NHS National Health Service NICE National Institute for Health and Care Excellence NPI Neuropsychiatric Inventory PBS Pharmaceutical Benefit Scheme PDD (...) . However, most evidence is based on common dementia types, particularly Alzheimer’s dementia; this needs to be borne in mind by the user when applying the evidence to other dementia types. Clinicians’ attention is also drawn to the fact that many psychotropic medications are used “off label” for people with dementia, particularly antipsychotic medication. While this is not prohibited by medicine regulations, it does require particular caution by the prescriber. This National Clinical Guideline

2019 National Clinical Guidelines (Ireland)

17. Medical Training to Achieve Competency in Lifestyle Counseling: An Essential Foundation for Prevention and Treatment of Cardiovascular Diseases and Other Chronic Medical Conditions: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

, role-playing, and motivational interviewing. They suggested that a systems approach that includes both providers and patients in the training program would be a very strong and promising model for lifestyle medicine education. Curricula Evaluation by Medical Students Every year, graduating medical students are surveyed by the AAMC about their perception of the quality of their medical school program. Questions cover a wide range of topics. In the 2013 survey, when graduates were asked to rank from (...) and prerequisite education for providers. Such a paradigm shift begins with medical education and adequate training. Medical schools have the opportunity to shape global health by incorporating lifestyle medicine as part of future physician preparation to practice medicine in the 21st century. The AHA is committed to supporting the transformation of medical education to achieve this goal. The goal of this scientific statement is to provide guidance in defining fundamentals in medical education and training

2016 American Heart Association

18. Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide

care. One important aspect of a structured medication review is to take into account all prescribed, OTC and complementary medicines that the person is taking or using, and what these are for. This might help to reduce duplication of medicines and the risk of accidental self-poisoning. Additional care might also be needed where more than 1 drug associated with suicide risk (a drug associated with an increased risk of suicidal thoughts) or increased toxicity in overdose (a drug that is particularly (...) optimisation: key therapeutic topic on medicines optimisation in chronic pain for prescribing data and metrics relating to prescribing controlled drugs. Health Education England and the National Collaborating Centre for Mental Health have launched a series of self-harm and suicide prevention competency frameworks. These describe activities that need to be brought together to support people who self-harm and/or are suicidal. The frameworks, help describe the work that is required within the following

2019 National Institute for Health and Clinical Excellence - Advice

19. 12?step programs for reducing illicit drug use Full Text available with Trip Pro

and economic costs of illicit drug use motivate the strong political interest in treatment for illicit drug use and in identifying effective treatments. The main types of treatment are cognitive‐behavioural therapies, motivational enhancement, contingency management, psychoanalysis, network therapy and – the object of this review –12‐step programs (Galanter & Kleber, 2008). 1.2 DESCRIPTION OF THE INTERVENTION 12‐step approaches to the treatment of drug use are widespread in many countries. The oldest (...) enhancement therapy, relapse prevention). They concluded that 12‐step approaches were as effective as alternative approaches in terms of improving drinking consequences, and reduction of alcohol consumption. Ferri and colleagues did not explicitly exclude co‐dependence on illicit drugs, nor did they report whether participants, in the eighttrials that were included in the review, had comorbid substance dependence. Treatment effectiveness for comorbid participants treated for alcohol disorder might inform

2017 Campbell Collaboration

20. Methamphetamine (Canadian Drug Summary)

Methamphetamine seizures in Medicine Hat increased from 369 grams in 2015 to 3,207 grams in 2017, an increase of almost 870%. ? International: The 2018 World Drug Report indicated that global quantities of methamphetamine seized in 2016 increased for a fourth consecutive year at 12%. 16 Methamphetamine also made up 12% of global drug seizures in 2015–2016 and was the third most common drug category seized after cannabis herb and cannabis resin. Methamphetamine also accounted for the largest share of global (...) Methamphetamine (Canadian Drug Summary) www.ccsa.ca • www.ccdus.ca November 2018 Canadian Drug Summary Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 Methamphetamine Introduction Methamphetamine is a synthetic drug classified as a central nervous system (CNS) stimulant or psychostimulant. CNS stimulants cover a wide range of substances that act on the body by increasing the level of activity of the CNS and include caffeine

2018 Canadian Centre on Substance Abuse

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>